医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

ニュース
添付文書
薬の臨床実感＆助言集

ENHERTU

ENHERTU® Approved in the EU for the Treatment of HER2 Positive Metastatic Breast Cancer

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: ENHERTU

2021年01月20日

ADDING MULTIMEDIA — ENHERTU® Approved in the U.S. for the Treatment of Patients with Previously Treated HER2 Positive Advanced Gastric Cancer

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: ADDING MULTIMEDIA ENHERTU

2021年01月18日

ENHERTU® Approved in the U.S. for the Treatment of Patients With Previously Treated HER2 Positive Advanced Gastric Cancer

ENHERTU® Approved in the U.S. for the Treatment of Patients With Previously Treated HER2 Positive Advanced Gastric Cancer

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: ENHERTU

2021年01月16日

ENHERTU® Continues to Demonstrate Durable Responses with New Data from DESTINY-Breast01 in HER2 Positive Metastatic Breast Cancer

ヘルスケア腫瘍学臨床試験製薬　 TimeLine: Continues to Demonstrate Durable Responses with ENHERTU from DESTINY-Breast01 in HER2 Positive Metastatic Breast Cancer

2020年12月10日

ENHERTU® Approved in Japan for the Treatment of Patients with HER2 Positive Metastatic Gastric Cancer

その他ヘルスヘルスケアヘルス一般腫瘍学臨床試験製薬遺伝学　 TimeLine: ENHERTU

2020年09月25日

ENHERTU® Significantly Improved Tumor Response Rate and Overall Survival in HER2 Positive Metastatic Gastric Cancer in Pivotal Phase 2 DESTINY-Gastric01 Trial

ENHERTU® Significantly Improved Tumor Response Rate and Overall Survival in HER2 Positive Metastatic Gastric Cancer in Pivotal Phase 2 DESTINY-Gastric01 Trial

ヘルスケア腫瘍学臨床試験製薬　 TimeLine: DESTINY-Gastric01 Trial ENHERTU Significantly Improved Tumor Response Rate and Overall Survival in HER2 Positive Metastatic Gastric Cancer in Pivotal Phase

2020年05月29日

ENHERTU® Demonstrated Meaningful Clinical Activity in Patients with HER2 Mutant Non-Small Cell Lung Cancer in Interim Analysis of Phase 2 DESTINY-Lung01 Trial

ENHERTU® Demonstrated Meaningful Clinical Activity in Patients with HER2 Mutant Non-Small Cell Lung Cancer in Interim Analysis of Phase 2 DESTINY-Lung01 Trial

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: Demonstrated Meaningful Clinical Activity in Patients with HER2 Mutant Non-Small Cell Lung Cancer in Interim Analysis of Phase DESTINY-Lung01 Trial ENHERTU

2020年05月29日

ENHERTU® Achieved a Tumor Response Rate of 45.3% in Patients with HER2 Positive Metastatic Colorectal Cancer in Phase 2 DESTINY-CRC01 Trial

ENHERTU® Achieved a Tumor Response Rate of 45.3% in Patients with HER2 Positive Metastatic Colorectal Cancer in Phase 2 DESTINY-CRC01 Trial

その他ヘルスバイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: DESTINY-CRC01 Trial ENHERTU

2020年05月29日

ENHERTU® Granted Orphan Drug Designation in the U.S. for Gastric Cancer

ENHERTU® Granted Orphan Drug Designation in the U.S. for Gastric Cancer

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: ENHERTU for Gastric Cancer Granted Orphan Drug Designation in the

2020年05月22日

ENHERTU® Granted Breakthrough Therapy Designation in the U.S. for HER2 Mutant Metastatic Non-Small Cell Lung Cancer

ENHERTU® Granted Breakthrough Therapy Designation in the U.S. for HER2 Mutant Metastatic Non-Small Cell Lung Cancer

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: ENHERTU for HER2 Mutant Metastatic Non-Small Cell Lung Cancer Granted Breakthrough Therapy Designation in the

2020年05月18日